REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for toughest lymphomas: experimental combo targets Cancer's repair system
Disease control CompletedThis early-stage study tested a new combination of drugs for patients with aggressive lymphomas that have come back or not responded to standard treatments. The main goal was to find the safest dose of a drug called olaparib when given with a powerful chemotherapy regimen before …
Matched conditions: REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New combo attack on Tough-to-Treat cancers
Disease control CompletedThis study tested whether combining a type of immunotherapy (pembrolizumab) with targeted radiation could help patients whose aggressive non-Hodgkin lymphoma had come back or stopped responding to other treatments. The goal was to see if the combination could shrink tumors and co…
Matched conditions: REFRACTORY T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC